Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company, will release its fourth-quarter and ...

Mineralys Therapeutics (MLYS) has completed enrollment in the Explore-CKD Phase 2 trial evaluating the efficacy and safety of lorundrostat for ...

RADNOR, Pa. - Mineralys Therapeutics , Inc. (NASDAQ:MLYS), a biopharmaceutical company specializing in the development of treatments for cardiovascular and kidney diseases, has announced the ...

Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) shot up 4% during trading on Friday .The stock traded as high as $13.43 and last traded at $13.39. 9,138 shares were traded ...

I believe Mineralys Therapeutics has a promising candidate with Lorundrostat for hypertension, CKD, and OSA. It should report more key pivotal clinical data this year. MLYS has several Phase 2 and ...

Jan. 08, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney ...

Mineralys Therapeutics, Inc. (MLYS) stock price is 10.30 and Mineralys Therapeutics, Inc. (MLYS) 10-day simple moving average is 10.02. Mineralys Therapeutics, Inc. (MLYS) stock price is 10.30 and ...

Mineralys Therapeutics, Inc. has a 52 week low of $7.95 and a 52 week high of $16.91. The company has a market capitalization of $491.22 million, a price-to-earnings ratio of -3.02 and a beta of 1.49.

Ericsson Posts Weak Results, Joins East West Bancorp And Other Big Stocks Moving Lower In Friday's Pre-Market Session ...

(RTTNews) - Mineralys Therapeutics, Inc. (MLYS), a clinical-stage biopharmaceutical company focused on developing treatments for hypertension and chronic kidney disease or CKD, on Tuesday ...

Today's IPO for Mineralys Therapeutics, Inc. (Nasdaq: MLYS) opened for trading at $21.10 per share after pricing 12,000,000 shares at $16 per share. BofA Securities, Evercore ISI, ...